MUTE-Seq is a new liquid-biopsy method powered by an engineered ultra-precise CRISPR enzyme, FnCas9-AF2, which can distinguish single-base mismatches across all sgRNA positions with near-zero ...
If you have been wondering whether CRISPR Therapeutics at around $57 a share is a bargain or a bubble, you are not alone. This stock sits at the crossroads of high science and high expectations. The ...
According to Precedence Research, the global gRNA market size is expected to grow from USD 708.92 million in 2025 to nearly ...
A team of researchers at the Icahn School of Medicine at Mount Sinai has uncovered why children with the same ...
A team of researchers at the Icahn School of Medicine at Mount Sinai has uncovered why children with the same ...
To the research team working to save him, KJ Muldoon was first known only as Patient Eta. But within months, KJ’s name — and ...
This year, gene-editing technology was customized to fix mutations in a single patient’s genes for the first time.
The United States DNA polymerase market is projected to reach USD 246.9 million by 2035, supported by rising investments in ...
Both stocks are risky, but one is far less so. This juicy upside potential comes at a cost. Investors seeking stocks with ...
The problem, Zaaijer explained, is that algorithms used in precision medicine models overwhelming are built on DNA with ...
Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced the publication of ...
Casgevy, now a "national priority" drug, helped kids with sickle cell and thalassemia, results which may help toward a label ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback